Does sotagliflozin reduce cardiovascular death and heart failure events in patients with diabetes and recent worsening heart failure?
In patients with diabetes and recent worsening heart failure, sotagliflozin initiated around the time of discharge significantly reduces cardiovascular deaths and heart failure events.
In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).
Bhatt et al. (2020) studied this question.